Literature DB >> 20686521

Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy.

Xiao-zhong Zhu1, Hong-mei Yin, Jiong Mei.   

Abstract

AIM: To investigate whether a combination of conventional and metronomic scheduling of chemotherapy could enhance and extend the effectiveness of chemotherapy against osteosarcoma.
METHODS: A total of 110 osteosarcoma-bearing SD rats were randomly divided into four groups, three of which were given conventional, metronomic or combination scheduling of chemotherapy, and the remaining one served as a control. Tumor volumes were measured every week during the treatment period of 8 weeks. At the end of treatment, tumors were removed from the rats and weighed. Expression of VEGFA in tumors was determined using Western blot assays.
RESULTS: As indicated by the tumor volume, conventional and metronomic schedules showed similar trends in tumor growth curves, and both of them lost their inhibitory effect in the sixth week, whereas the combination schedule maintained effectiveness until the end of treatment. Statistical significance with tumor volumes and weights was found among the groups (P<0.001), with combination scheduling being the most effective (P<0.001). Western blot indicated that all the therapy groups had significantly decreased expression of VEGFA (P<0.01), and the combination scheduling group had the lowest VEGFA expression.
CONCLUSION: Combination of conventional and metronomic scheduling of chemotherapy could be a promising treatment for osteosarcoma. Antiangiogenesis contributed to the effect of combination scheduling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686521      PMCID: PMC4007816          DOI: 10.1038/aps.2010.97

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  29 in total

1.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

Authors:  D Hanahan; G Bergers; E Bergsland
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.

Authors:  Giannoula Klement; Ping Huang; Barbara Mayer; Shane K Green; Shan Man; Peter Bohlen; Daniel Hicklin; Robert S Kerbel
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

3.  Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.

Authors:  D H Lau; L Xue; L J Young; P A Burke; A T Cheung
Journal:  Cancer Biother Radiopharm       Date:  1999-02       Impact factor: 3.099

4.  "Metronomic" chemotherapy in advanced soft tissue sarcomas.

Authors:  Antoine Italiano; Maud Toulmonde; Barbara Lortal; Eberhard Stoeckle; Delphine Garbay; Guy Kantor; Michèle Kind; Jean-Michel Coindre; Binh Bui
Journal:  Cancer Chemother Pharmacol       Date:  2010-02-25       Impact factor: 3.333

5.  Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.

Authors:  Terence C Tang; Shan Man; Christina R Lee; Ping Xu; Robert S Kerbel
Journal:  Neoplasia       Date:  2010-03       Impact factor: 5.715

Review 6.  Current treatment of osteosarcoma.

Authors:  W S Ferguson; A M Goorin
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

7.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Authors:  T Browder; C E Butterfield; B M Kräling; B Shi; B Marshall; M S O'Reilly; J Folkman
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

8.  Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma.

Authors:  Tong-Xin Xie; Zhibo Xia; Nu Zhang; Weida Gong; Suyun Huang
Journal:  Oncol Rep       Date:  2010-03       Impact factor: 3.906

9.  Expression of Efp, VEGF and bFGF in normal, hyperplastic and malignant endometrial tissue.

Authors:  Hongying Dai; Shuping Zhao; Lin Xu; Aiping Chen; Shuzhen Dai
Journal:  Oncol Rep       Date:  2010-03       Impact factor: 3.906

10.  Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.

Authors:  K K Y Cham; J H E Baker; K S Takhar; J A Flexman; M Q Wong; D A Owen; A Yung; P Kozlowski; S A Reinsberg; E M Chu; C-W A Chang; A K Buczkowski; S W Chung; C H Scudamore; A I Minchinton; D T T Yapp; S S W Ng
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

View more
  2 in total

1.  Programmed cell death 2 functions as a tumor suppressor in osteosarcoma.

Authors:  Yuanxun Yang; Yan Jin; Wenxi Du
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

2.  Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy.

Authors:  Luisina M Solernó; Natasha T Sobol; María F Gottardo; Carla S Capobianco; Maximiliano R Ferrero; Liliana Vásquez; Daniel F Alonso; Juan Garona
Journal:  Sci Rep       Date:  2022-09-08       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.